The local terminally inoperable non-small cell lung cancer: In the same period, chemotherapy is standard.

The local terminally inoperable non-small cell lung cancer: Over the same period, chemotherapy is the subject of standard treatment for the current period: partially terminally inoperable non-small cell lung cancerIn one sentence, the general content of the subject: partially terminally inoperable non-small cell lung cancer: Release of chemotherapy during the same period is standard treatment and has the opportunity for long-term survivalTypical cases:Three pictures of the CT were taken by an 71-year-old uncle of Shanghai in 2013, 2014 and 2020. The first CT on the left was a CT film at the time of the initial outbreak in October 2013, when Uncle Shanghai was diagnosed in Shanghai City chest hospital as partially subdivided non-small cell lung cancer at the end of a clinical period of c-T4N2M0, IIIB, where the patient could not be operated after multidisciplinary discussions. The treatment was then carried out during the same period at the Shanghai chest hospital. The second CT in the left is a CT film that was reviewed after treatment at the Shanghai City chest hospital in July 2014, and it can be seen that the red circle has completely disappeared. The patient was then followed by a regular CT at the Shanghai Breast Hospital, the last of which was in January 2020, and the third from the left was the last of the visits, until the last visit to the hospital, where no anomalies were detected. The patient received a telephone follow-up on 23 September 2022, without any discomfort, and is scheduled to follow up in the near future.Doctors point out that lung cancer consists of small-cell lung cancer and non-small-cell lung cancer, which accounts for approximately 85 per cent of non-small-cell lung cancer, and non-small-cell lung cancer, which mainly includes gland and gland cancer. When patients are diagnosed, a significant proportion of them are partially advanced, and a significant part of them are non-operative. The treatment of non-small-cell lung cancer, which is partially terminally non-operative, involves a wide range of management, with recommendations focusing on integrated treatment programmes, effective side effects management, measures to prevent relapse and multi-faceted care to improve the quality of life. The development of individualized treatment programmes and individualized programmes based on the patient ‘ s specific stage, physical condition, genetic test results, etc. The local end-of-life NSCLC is the standard treatment, and patients are expected to achieve long-term survival through the same period. However, the specific dose, frequency of treatment and combination of drugs need to be adapted to the patient ‘ s endurance and condition, especially for infirm or elderly patients. In recent years, the use of immunisation treatment for lung cancer has become increasingly widespread, and for patients with local late non-minocellular lung cancer, access to immunisation treatment is expected to be more effective, based on the same period of free chemotherapy. The combination of immunotherapy and chemotherapy, which enhances the activity against tumours, and combined therapy, which in some cases also shows very significant efficacy, shows that immunotherapy can help the body immune system to identify and attack residual tumour cells more effectively, especially for those at higher risk of relapse. After treatment, there is also a need for regular follow-up and monitoring with the patient, who is advised to conduct regular video and blood tests, as prescribed by the doctor, to monitor the recurrence or transfer of the tumor. Early detection of relapses is likely to yield better results in second-line treatment, and therefore close follow-up is also an important element of the final non-surgery of the NSCLC in the Department of the Successful Authority. When it comes to routine follow-up treatment, what is essential is a change in the way in which daily life is carried out, and maintaining a healthy diet and an adequate amount of exercise can significantly improve the quality of life of patients and help to mitigate the side effects of treatment. Avoid exposure to air pollution and hazardous chemicals in order to reduce further damage to the lungs. It was generally recommended that patients with limitations that could not be operated on NSCLC should stop smoking and alcohol, as tobacco and alcohol could increase the lung burden and possibly reduce the efficacy of treatment. At the same time, where physical capacity permits, modest activities can help improve lung function and cardiovascular health. Low-intensity walking, stretching, etc. are generally recommended to increase immunity and resistance, but to avoid intense activity and to avoid an increased respiratory burden. Dietary regulation, high-protein, vitamin-rich diets help accelerate recovery from chemotherapy. Avoid high sugar and fat foods and select foods with antioxidants, such as green leaf vegetables, fruits, nuts, etc., to enhance the body ‘ s ability to repair them. Scientific treatment and life management, through standardized combination treatment and individualized treatment strategies, provide patients with better control and quality of life. Lung cancer